Comparing SG&A Expenses: Gilead Sciences, Inc. vs Galapagos NV Trends and Insights

SG&A Expenses: A Tale of Two Biotech Giants

In the competitive world of biotechnology, understanding the financial strategies of industry leaders is crucial. Gilead Sciences, Inc. and Galapagos NV, two prominent players, have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade.

Gilead Sciences, Inc.: A Steady Climb

From 2014 to 2023, Gilead Sciences, Inc. has consistently increased its SG&A expenses, peaking at approximately $6.09 billion in 2023. This represents a 104% increase from 2014, reflecting the company's aggressive expansion and marketing strategies.

Galapagos NV: A Volatile Journey

In contrast, Galapagos NV's SG&A expenses have been more volatile, with a significant spike in 2022, reaching around $239 million. This fluctuation indicates strategic shifts and potential market adaptations.

Insights and Implications

These trends highlight the differing approaches of these biotech giants in managing operational costs, with Gilead focusing on steady growth and Galapagos adapting to market dynamics.